Mika to raise €10 million from invetsors led by Debiopharm Innovation Fund, joined by Ship2B Ventures, Equity Pitcher and Ananda Impact Ventures.

Mika, a Berlin, Germany-based digital healthcare provider of support services for cancer patients, raised a seed funding round closed at €10 million ($10.5M).

The money was raised investors led by Debiopharm Innovation Fund, joined by Ship2B Ventures, an Ananda Impact Ventures.

Proceeds will be used to enter the U.K. healthcare ecosystem in 2022 as well as for partnering with international cancer research centres to conduct even more studies on the medical impact of AI-driven personalisation in digital interventions.

Mika, founded in 2017 by Gandolf Finke and Jan Simon Raue, developed Fosanis, a mobile app used for digital therapy support for cancer patients, helping them with knowledge, tips and exercises for everyday life in order to experience a better quality of life despite cancer. The company provides personalised and comprehensive cancer therapy support, combining the latest insights in cancer research with 24/7 hands-on help wrapped up in an easy-to-handle and engaging digital tool.

Mika previously raised funding in 2019 and in 2021, backed also by IBB Ventures and the investment company Evodia.